TransMedics Group, Inc. (TMDX) Stock
TMDX Key Statistics
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
CEO: Waleed H. Hassanein. Company website
TMDX — Frequently Asked Questions
What is the TMDX stock price today?
TransMedics Group, Inc. (TMDX) trades at $86.42, down 0.28% on the day, as of Sep 20, 2026 15:00 UTC.
What is TransMedics Group, Inc.'s market cap?
TransMedics Group, Inc. has a market capitalisation of $2.99B, calculated from the live TMDX share price and shares outstanding.
What is the P/E ratio of TMDX?
TMDX trades at a trailing P/E of 22.39, from earnings per share of $3.86 over the last twelve months.
How much revenue does TransMedics Group, Inc. make?
TransMedics Group, Inc. generated revenue of $668.47M over the trailing twelve months, which puts the stock at 4.47 times sales.
What is the 52-week range for TMDX?
TMDX has traded between $60.11 and $156.00 over the past 52 weeks, and the last price is 44.6% below that high.
Is TransMedics Group, Inc. profitable?
Yes. TransMedics Group, Inc. keeps 22.69% of revenue as net income over the trailing twelve months.
What is the analyst price target for TMDX?
Wall Street analysts rate TMDX Buy, with an average price target of $96.86, 12.1% above the current price.
What sector is TransMedics Group, Inc. in?
TransMedics Group, Inc. is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US.
Who is the CEO of TransMedics Group, Inc.?
Waleed H. Hassanein is the chief executive of TransMedics Group, Inc., which employs 898 people.
Where can I track TMDX in real time?
QFI Terminal shows TMDX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See TMDX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open TMDX in Terminal See plans